Geron-logo-black-xsmall.png
Geron Announces Plans for Imetelstat Phase 3 Clinical Trial in Myelofibrosis and Other Updates
May 21, 2020 16:01 ET | Geron Corporation
Geron plans to move forward with a Phase 3 clinical trial in refractory myelofibrosis (MF) with overall survival (OS) as a primary endpoint, which is expected to open for screening and enrollment in...
CPI Logo-Color.png
Constellation Pharmaceuticals Provides Update of Preliminary Data for CPI-0610 in Three EHA Abstracts
May 14, 2020 08:00 ET | Constellation Pharmaceuticals , Inc.
Continued high rate of SVR35 in 1L patients: 72% at 12 weeks and 67% at 24 weeksSVR35 responses and transfusion dependence conversion observed in 2L monotherapy patients Improvement in bone marrow...
CPI Logo-Color.png
Constellation Pharmaceuticals Announces First-Quarter 2020 Financial Results
May 06, 2020 07:00 ET | Constellation Pharmaceuticals , Inc.
EHA abstracts to publish on May 14 with an interim update across the MANIFEST trial cohortsConstellation to provide an additional interim update from MANIFEST at EHA in mid-June Company continues to...
Geron-logo-black-xsmall.png
Geron to Present at Needham Virtual Healthcare Conference
April 08, 2020 16:30 ET | Geron Corporation
MENLO PARK, Calif., April 08, 2020 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that John A. Scarlett, M.D., Chairman and Chief Executive Officer, is scheduled to present a...
Geron-logo-black-xsmall.png
Geron Provides COVID-19 Related Business Update
April 02, 2020 08:00 ET | Geron Corporation
MENLO PARK, Calif., April 02, 2020 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a late-stage clinical development biopharmaceutical company, today announced an update to information from...
CPI Logo-Color.png
Constellation Pharmaceuticals to Present at J.P. Morgan Healthcare Conference
January 06, 2020 12:33 ET | Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., Jan. 06, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover...
CPI Logo-Color.png
Constellation Pharmaceuticals Announces Proposed Public Offering of Common Stock
December 09, 2019 16:18 ET | Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., (Nasdaq: CNST) a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover...
CPI Logo-Color.png
Constellation Pharmaceuticals Provides Updated Preliminary Data from MANIFEST Clinical Trial with CPI-0610 in Oral and Poster Presentations at ASH
December 09, 2019 10:00 ET | Constellation Pharmaceuticals , Inc.
Preliminary data showed continuing signs of activity across a broad range of parameters, suggesting possible disease-modifying effects of CPI-0610In the first-line treatment arm, 12 out of 15 (80%)...
CPI Logo-Color.png
Constellation Pharmaceuticals to Host Analyst/Investor Meeting at ASH to Discuss Updated Preliminary Data from the MANIFEST Clinical Trial with CPI-0610
December 02, 2019 11:00 ET | Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., Dec. 02, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and...
Geron-logo-black-xsmall.png
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 21, 2019 08:00 ET | Geron Corporation
MENLO PARK, Calif., Nov. 21, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 150,000 shares of...